CD19 and B-cell chronic lymphocytic leukemia: To investigate if drug-mediated ROS acceleration is responsible for the synergistic effect of PipFcB, the combination of the two unspecific ROS accelerators—Fe(HQ)2 and Buthionine sulfoximine (BSO)—with CD19-specific CARTs was evaluated on CD19+ Daudi and primary CLL cells.